Table 1.
Findings from independent “diagnostic accuracy” studies of dedicated gamma cameras and PEM in which the primary enrollment criteria for subjects was a suspicious lesion identified by physical exam, mammography, or other imaging.
| Author | Year | Camera type | Radio-pharmaceutical | Administered activity (MBq) | Nuclear study interpretation | N | Sensitivity for all cancers3 | Sensitivity for cancers ≤10 mm3 | Sensitivity for DCIS3 | Specificity for benign lesions3 |
|---|---|---|---|---|---|---|---|---|---|---|
| De Vincentis (Ref. 35) | 1997 | Single-head CsI-PSPMT gamma camera | Tc-99m sestamibi | 740 | Not reported | 7 | 4/4 (100) | 3/3 (100) | – | 3/3 (100) |
| Pani (Ref. 44) | 1998 | Single-head CsI-PSPMT gamma camera | Tc-99m sestamibi | 740 | Not reported | 14 | 9/11 (82) | 5/7 (71) | – | 2/3 (67) |
| Maini (Ref. 211) | 1999 | Single-head CsI-PSPMT gamma camera | Tc-99m sestamibi | 740 | Not reported | 29 | 16/19 (84) | 6/9 (67) | – | 8/10 (80) |
| Scopinaro (Ref. 23) | 1999 | Single-head CsI-PSPMT gamma camera | Tc-99m sestamibi | 740 | Blinded | 53 | 27/31 (87) | 13/16 (81) | – | 19/22 (86) |
| Brem (Ref. 19) | 2002 | Single-head NaI-PSPMT gamma camera | Tc-99m sestamibi | 925 | Blinded | 50 | 22/28 (79) | 10/15 (67) | – | 28/30 (93) |
| O'Connor (Ref. 212) | 2007 | Single-head CZT gamma camera | Tc-99m sestamibi | 740 | Access to MG and US findings | 99 | 57/67 (85) | 26/35 (74) | 8/8 (100) | 36/47 (77) |
| Spanu (Ref. 213) | 2007 | single-head CZT gamma camera | Tc-99m tetrofosmin | 740 | Blinded | 85 | 87/90 (97) | 28/31 (90) | – | 11/12 (92) |
| Brem (Ref. 214) | 2008 | Single-head NaI-PSPMT gamma camera | Tc-99m sestamibi | 925–1110 | In clinical practice, access to available imaging | 146 | 80/83 (96) | 17/20 (85) | 15/16 (94) | 50/84 (60) |
| Hruska (Ref. 55) | 2008 | Dual-head CZT gamma camera | Tc-99m sestamibi | 740 | Blinded | 150 | 115/128 (90) | 50/61 (82) | 16/17 (94) | 42/61 (69) |
| Spanu (Ref. 215) | 2008 | Single-head CZT gamma camera | Tc-99m tetrofosmin | 740 | Blinded | 145 | 139/143 (97) | 41/45 (91) | – | 19/22 (86) |
| Total | 778 | 556/604 (92) | 199/242 (82) | 39/41 (95) | 218/294 (74) | |||||
| Murthy (Ref. 216) | 2000 | Dual-head BGO-PSPMT PEM system | F-18 FDG | 75 | Access to MG findings | 14 | 8/10 (80) | – | – | 4/4 (100) |
| Levine (Ref. 217) | 2003 | Dual-head GSO-PSPMT PEM system | F-18 FDG | 370 | Access to MG findings | 16 | 6/7 (86) | 4/4 (100) | 2/2 (100) | 10/11 (91) |
| Rosen (Ref. 85) | 2005 | Dual-head LGSO-PSPMT PEM system | F-18 FDG | 74–93 | Access to MG findings | 23 | 18/21 (86) | 2/3 (67) | 2/3 (100) | 1/3 (33) |
| Berg (Ref. 218) | 2006 | Dual-head LYSO-PSPMT PEM system | F-18 FDG | 300–795 | Access to MG findings | 77 | 39/42 (93) | 5/8 (63) | 10/11 (91) | 29/35 (83) |
| Total | 130 | 75/86 (87) | 11/15 (73) | 14/16 (88) | 53/62 (85) |
1
Numbers in parentheses are percentages and are rounded.
2
N = number of analyzable participants. MG = mammography. US = ultrasound. DCIS = ductal carcinoma in situ.
3
Sensitivity and specificity are reported on the per lesion level and some patients had more than one lesion.